Enhanced immunogenicity of modified hepatitis B virus core particle fused with multiepitopes of foot-and-mouth disease virus
- PMID: 17386022
- DOI: 10.1111/j.1365-3083.2007.01900.x
Enhanced immunogenicity of modified hepatitis B virus core particle fused with multiepitopes of foot-and-mouth disease virus
Abstract
Hepatitis B virus core (HBc) particles, self-assemble into capsid particles and are extremely immunogenic, hold promise as an immune-enhancing vaccine carrier for heterologous antigens. However, formation of virus-like particles (VLP) can be restricted by size and structure of heterlogous antigens. In the study, we investigated formation of VLP by modified HBc fused with specified foot-and-mouth disease virus (FMDV) multiepitopes and evaluated their immune effects. Firstly, three HBc display vectors (pHBc1, pHBc2 and pHBc3) were constructed by deletions of different lengths within the HBc c/e1 region: 75-78 amino acid (aa), 75-80 aa and 75-82 aa respectively. Secondly, we inserted different compositions of FMDV multiepitopes, BT [VP1(141-160)-VP4(21-40)] and BTB [VP1(141-160)-VP4(21-40)-VP1(141-160)], into modified regions. As a result, only plasmid pHBc3-BTB of six recombinant vectors was expressed as soluble protein, which resulted in the formation of complete VLP confirmed by electron microscopy. Recombinant VLP could be taken up by cells and presented in vitro and in vivo. Furthermore, the modified VLP displayed a significantly stronger immunogenicity than other five recombinant proteins and GST-BTB with a higher titer of peptide-specific and virus-specific antibody, elevated IFN-gamma and interleukin-4 production, especially enhanced lymphocyte proliferation. The results encourage further work towards the development of FMDV vaccines using hepatitis B virus core particles fused with FMDV epitopes.
Similar articles
-
DNA vaccines expressing B and T cell epitopes can protect mice from FMDV infection in the absence of specific humoral responses.Vaccine. 2006 May 1;24(18):3889-99. doi: 10.1016/j.vaccine.2006.02.028. Epub 2006 Mar 3. Vaccine. 2006. PMID: 16563575
-
Immunogenicity of a recombinant fusion protein of tandem repeat epitopes of foot-and-mouth disease virus type Asia 1 for guinea pigs.Acta Virol. 2002;46(1):1-9. Acta Virol. 2002. PMID: 12199204
-
Immunogenicity of the epitope of the foot-and-mouth disease virus fused with a hepatitis B core protein as expressed in transgenic tobacco.Viral Immunol. 2005;18(4):668-77. doi: 10.1089/vim.2005.18.668. Viral Immunol. 2005. PMID: 16359233
-
Hybrid hepatitis B virus core antigen as a vaccine carrier moiety: I. presentation of foreign epitopes.J Biotechnol. 1996 Jan 26;44(1-3):91-6. doi: 10.1016/0168-1656(95)00118-2. J Biotechnol. 1996. PMID: 8717391 Review.
-
Development of recombinant Salmonellae expressing hybrid hepatitis B virus core particles as candidate oral vaccines.Dev Biol Stand. 1994;82:151-8. Dev Biol Stand. 1994. PMID: 7958469 Review.
Cited by
-
Cell-permeable capsids as universal antigen carrier for the induction of an antigen-specific CD8+ T-cell response.Sci Rep. 2017 Aug 29;7(1):9630. doi: 10.1038/s41598-017-08787-0. Sci Rep. 2017. PMID: 28851900 Free PMC article.
-
Hepatitis B core-based virus-like particles: A platform for vaccine development in plants.Biotechnol Rep (Amst). 2021 Feb 28;29:e00605. doi: 10.1016/j.btre.2021.e00605. eCollection 2021 Mar. Biotechnol Rep (Amst). 2021. PMID: 33732633 Free PMC article. Review.
-
Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses.J Virol. 2008 Dec;82(23):11813-23. doi: 10.1128/JVI.01076-08. Epub 2008 Sep 10. J Virol. 2008. PMID: 18786995 Free PMC article.
-
Rational design of novel fusion rabies glycoproteins displaying a major antigenic site of foot-and-mouth disease virus for vaccine applications.Appl Microbiol Biotechnol. 2022 Jan;106(2):579-592. doi: 10.1007/s00253-021-11747-4. Epub 2021 Dec 31. Appl Microbiol Biotechnol. 2022. PMID: 34971413 Free PMC article.
-
Plant-derived VLP: a worthy platform to produce vaccine against SARS-CoV-2.Biotechnol Lett. 2022 Jan;44(1):45-57. doi: 10.1007/s10529-021-03211-0. Epub 2021 Nov 27. Biotechnol Lett. 2022. PMID: 34837582 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials